ContraFect Corporation (CFRX): Price and Financial Metrics


ContraFect Corporation (CFRX): $3.64

0.26 (+7.69%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CFRX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CFRX Stock Price Chart Interactive Chart >

Price chart for CFRX

CFRX Price/Volume Stats

Current price $3.64 52-week high $4.76
Prev. close $3.38 52-week low $2.11
Day low $3.35 Volume 82,900
Day high $3.65 Avg. volume 86,863
50-day MA $3.67 Dividend yield N/A
200-day MA $3.41 Market Cap 143.17M

ContraFect Corporation (CFRX) Company Bio


ContraFect Corporation, a biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases in the United States. The company was founded in 2008 and is based in Yonkers, New York.


CFRX Latest News Stream


Event/Time News Detail
Loading, please wait...

CFRX Latest Social Stream


Loading social stream, please wait...

View Full CFRX Social Stream

Latest CFRX News From Around the Web

Below are the latest news stories about CONTRAFECT Corp that investors may wish to consider to help them evaluate CFRX as an investment opportunity.

ContraFect (CFRX) Investor Presentation - Slideshow

The following slide deck was published by ContraFect Corporation in conjunction with this event....

SA Transcripts on Seeking Alpha | February 24, 2022

ContraFect (CFRX) Receives a Buy from Leerink Partners

Leerink Partners analyst Roanna Ruiz maintained a Buy rating on ContraFect (CFRX – Research Report) today and set a price target of $9.00. The company's shares closed last Tuesday at $3.33. According to TipRanks.com, Ruiz 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -34.1% and a 18.8% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Xeris Pharmaceuticals, and Atea Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for ContraFect with a $10.25 average price target, implying a 222.3% upside from current levels.

Christine Brown on TipRanks | February 16, 2022

ContraFect to Present at the SVB Leerink 11th Annual Global Healthcare Conference

YONKERS, N.Y., Feb. 10, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of ContraFect, will participate in a fireside chat at the SVB Leerink 11 th Annual Global Healthcare Conference, which is being held virtually from February 14–18, 2022. The fireside chat will be held on Thursday, February 17, 2022 at 10:00 AM ET.

GlobeNewswire | February 10, 2022

ContraFect Announces Award from the Cystic Fibrosis Foundation to Evaluate Exebacase as a Potential Treatment for Serious MRSA Lung Infections Associated with Cystic Fibrosis

YONKERS, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces that it has received an additional award from the Cystic Fibrosis Foundation (CFF). This contract award will support investigation of the potent

Yahoo | January 6, 2022

How Much Of ContraFect Corporation (NASDAQ:CFRX) Do Institutions Own?

A look at the shareholders of ContraFect Corporation ( NASDAQ:CFRX ) can tell us which group is most powerful...

Yahoo | January 1, 2022

Read More 'CFRX' Stories Here

CFRX Price Returns

1-mo -2.41%
3-mo 8.98%
6-mo 3.41%
1-year -9.45%
3-year -9.70%
5-year -74.00%
YTD 38.40%
2021 -47.92%
2020 -18.64%
2019 -59.43%
2018 51.49%
2017 -42.29%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9364 seconds.